Ligand Pharmaceuticals Shares Drop After Plans to Offer $550M in Notes

Dow Jones06-22

By Chris Wack

Ligand Pharmaceuticals shares were 8% lower, at $254.01, after the company said it plans to offer $550 million of convertible senior notes due 2031 in a private placement.

Ligand said it expects to grant to the initial purchasers of the notes a 13-day option to buy up to an additional $82.5 million of notes.

The notes will be general unsecured, senior obligations of Ligand, and will accrue interest payable semiannually each March 15 and Sept. 15, beginning on March 15, 2027.

The notes will mature Sept. 15, 2031, unless earlier converted, redeemed or repurchased.

Ligand expects to use up to $75 million of the proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions. The company said it intends to use the remaining proceeds for general corporate purposes, including investing in complementary businesses, companies, products and technologies.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 22, 2026 10:29 ET (14:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645344073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645344073","market":"nz","top_or_hot":-1,"title":"Ligand Pharmaceuticals Shares Drop After Plans to Offer $550M in Notes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ligand Pharmaceuticals shares were 8% lower, at $254.01, after the company said it plans to offer $550 million of convertible senior notes due 2031 in a private placement. \n</p>\n<p>\n  Ligand said it expects to grant to the initial purchasers of the notes a 13-day option to buy up to an additional $82.5 million of notes. \n</p>\n<p>\n  The notes will be general unsecured, senior obligations of Ligand, and will accrue interest payable semiannually each March 15 and Sept. 15, beginning on March 15, 2027. \n</p>\n<p>\n  The notes will mature Sept. 15, 2031, unless earlier converted, redeemed or repurchased. \n</p>\n<p>\n  Ligand expects to use up to $75 million of the proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions. The company said it intends to use the remaining proceeds for general corporate purposes, including investing in complementary businesses, companies, products and technologies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand Pharmaceuticals Shares Drop After Plans to Offer $550M in Notes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand Pharmaceuticals Shares Drop After Plans to Offer $550M in Notes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 22:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ligand Pharmaceuticals shares were 8% lower, at $254.01, after the company said it plans to offer $550 million of convertible senior notes due 2031 in a private placement. \n</p>\n<p>\n  Ligand said it expects to grant to the initial purchasers of the notes a 13-day option to buy up to an additional $82.5 million of notes. \n</p>\n<p>\n  The notes will be general unsecured, senior obligations of Ligand, and will accrue interest payable semiannually each March 15 and Sept. 15, beginning on March 15, 2027. \n</p>\n<p>\n  The notes will mature Sept. 15, 2031, unless earlier converted, redeemed or repurchased. \n</p>\n<p>\n  Ligand expects to use up to $75 million of the proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions. The company said it intends to use the remaining proceeds for general corporate purposes, including investing in complementary businesses, companies, products and technologies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645344073","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645344073","pubTimestamp":1782138540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ligand Pharmaceuticals shares were 8% lower, at $254.01, after the company said it plans to offer $550 million of convertible senior notes due 2031 in a private placement.Ligand said it expects to grant to the initial purchasers of the notes a 13-day option to buy up to an additional $82.5 million of notes.The notes will be general unsecured, senior obligations of Ligand, and will accrue interest payable semiannually each March 15 and Sept. 15, beginning on March 15, 2027.The notes will mature Sept. 15, 2031, unless earlier converted, redeemed or repurchased.Ligand expects to use up to $75 million of the proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions. The company said it intends to use the remaining proceeds for general corporate purposes, including investing in complementary businesses, companies, products and technologies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LGND":"Ligand Pharmaceuticals Inc.","BK4139":"生物科技","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"Ligand Pharmaceuticals计划发行5.5亿美元票据后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1.5},"content_text":"By Chris Wack \n\n\n \n\n\n  Ligand Pharmaceuticals shares were 8% lower, at $254.01, after the company said it plans to offer $550 million of convertible senior notes due 2031 in a private placement. \n\n\n  Ligand said it expects to grant to the initial purchasers of the notes a 13-day option to buy up to an additional $82.5 million of notes. \n\n\n  The notes will be general unsecured, senior obligations of Ligand, and will accrue interest payable semiannually each March 15 and Sept. 15, beginning on March 15, 2027. \n\n\n  The notes will mature Sept. 15, 2031, unless earlier converted, redeemed or repurchased. \n\n\n  Ligand expects to use up to $75 million of the proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions. The company said it intends to use the remaining proceeds for general corporate purposes, including investing in complementary businesses, companies, products and technologies. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 10:29 ET (14:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645344073","isCrawlerRequest":true}